Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) traded up 27.3% during mid-day trading on Friday . The company traded as high as $19.51 and last traded at $19.37. 510,895 shares were traded during mid-day trading, an increase of 920% from the average session volume of 50,104 shares. The stock had previously closed at $15.22.
Neoleukin Therapeutics Trading Down 5.0%
The stock has a market cap of $174.33 million, a price-to-earnings ratio of -5.96 and a beta of 1.11. The stock's 50-day moving average price is $13.57 and its 200-day moving average price is $19.93.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Further Reading
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
